Inhibrx Biosciences, Inc.
NMS: INBXLive Quote
About Inhibrx Biosciences, Inc.
Healthcare
Biotechnology
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
📊 Fundamental Analysis
Inhibrx Biosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -100.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -197.8%, which indicates that capital utilization is currently under pressure.
At a current price of $75.27, INBX currently sits at the 77th percentile of its 52-week range (Range: $10.84 - $94.56).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
Key Financials
Market Cap
$1.31B
Trailing P/E
--
Forward P/E
-26.98
Beta (5Y)
--
52W High
$94.56
52W Low
$10.84
Avg Volume
208K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App